Retatrutide, a triple antagonist, achieves record weight loss.

Published Date: 27 Jun 2023

Retatrutide, a molecule that acts as an agonist to the GLP-1, GIP, and glucagon receptors, was used in two early studies to treat people with type 2 diabetes and people without, and it was linked to weight loss never before seen.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot